相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
Alexis B. Cortot et al.
CANCER RESEARCH (2013)
Molecular Pathways: ROS1 Fusion Proteins in Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2013)
New Targetable Oncogenes in Non-Small-Cell Lung Cancer
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease
Kadoaki Ohashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
Soyeon Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The EGFR family members sustain the neoplastic phenotype of ALK plus lung adenocarcinoma via EGR1
C. Voena et al.
ONCOGENESIS (2013)
A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
K. E. Ware et al.
ONCOGENESIS (2013)
Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2012)
Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells
Tadaaki Yamada et al.
CLINICAL CANCER RESEARCH (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Treating ALK-positive lung cancer-early successes and future challenges
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Kadoaki Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
Dalia Ercan et al.
CANCER DISCOVERY (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Peter S. Hammerman et al.
CLINICAL CANCER RESEARCH (2009)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen et al.
CLINICAL CANCER RESEARCH (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels
Barbara A. Helfrich et al.
CLINICAL CANCER RESEARCH (2006)
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
Marissa N. Balak et al.
CLINICAL CANCER RESEARCH (2006)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
M Ronson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
